email article
Late dosing of common luteinizing hormone-releasing hormone (LHRH) agonists used for androgen deprivation therapy (ADT) in prostate cancer occurs frequently, a researcher reported.
Late dosing was particularly common (over 80%) when measured against the 28-day dosing schedules used in clinical trials for these therapies, and found in prescribing information, according to Julia Vandross, NP-BC, BSN, MSN, of Providence Saint John s Health Center in California.
The findings were presented in an e-poster at the Oncology Nursing Society virtual meeting, and recently published in Achieving and maintaining effective testosterone suppression to levels attained with surgical castration is the cornerstone of ADT for advanced prostate cancer, pointed out Vandross and colleagues. However, testosterone levels can rise above castrate level (50 ng/dL) between injections, particularly if those injections are administered late, they added.
Auricular acupressure can reduce chemotherapy-induced peripheral neuropathy (CIPN) symptoms following breast cancer treatment, South Korean researchers reported.
Their randomized trial showed that the technique significantly improved patient-reported CIPN symptoms compared with the use of a sham treatment. Results from the study, led by Mijung Kim, PhD, of the College of Nursing of Chungnam National University in Daejeon, were presented at the Oncology Nursing Society virtual annual meeting.
CIPN can occur following the administration of a variety of antineoplastic agents, such as taxanes, and can seriously affect quality of life, with symptoms sometimes lasting many months.
The problem is very common: in a 2014 review, the prevalence of CIPN one month after finishing chemotherapy was 68%, dropped to 60% at three months, and still occurred in 30% of patients at six months.
Are Post-Mastectomy Lymphedema Precautions Needed for All? medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.
APSHO Supports Full Scope-of-Practice Regulation for Advanced Practitioners in Open Letter to President Biden
Share Article
The Advanced Practitioner Society for Hematology and Oncology (APSHO), a society of nurse practitioners, physician assistants, pharmacists, and other health-care providers, encourages the administration to remove unnecessary practice barriers and expand patient access to health-care services. LAWRENCEVILLE, N.J. (PRWEB) April 21, 2021
The Advanced Practitioner Society for Hematology and Oncology (APSHO) sent an open letter to President Biden requesting support for regulatory changes that authorize advanced practitioners and other health professionals to practice to the full extent of their education, clinical competence, and experience during the COVID-19 pandemic.
th Annual Oncology Nursing Society (ONS) Congress. The virtual conference takes place on April 20, 22, 27 and 29, 2021. The nurse-led studies highlight the intersection of clinical knowledge, research, direct patient care and advocacy resulting in innovation. The ONS Congress is the largest, most comprehensive oncology nursing conference in the country.
The presentations focus on the effects of the COVID-19 crisis, the need for diversity, equity and inclusion in oncology nursing as well as the critical role oncology nurse navigators play in a patient’s treatment plan.
Notable presentations by Dana-Farber nurse/researchers include:
Primary Author: Renee Abdella, BSN, RN, OCN, BMTCN
Authors: Kathleen Spinello, DNP, RN, NE-BC; Rebecca Spitz, BSN, RN, OCN; Kimberly Mello, BSN, RN; Julie McCarthy, BSN, RN, PCCN; Jill Popp, BSN, RN, PCCN